23andMe's new BRCA1/BRCA2 (Selected Variants) report looks at three variants in the BRCA1 and BRCA2 genes associated with an increased risk of breast, ovarian and prostate cancer. These three variants are most common in people of Ashkenazi Jewish descent, but having one of these variants carries serious risk no matter your ancestry.

23andMe received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk for its BRCA1/BRCA2 report. The report covers three variants in the BRCA1 and BRCA2 genes associated with increased risk for breast, ovarian, and prostate cancer.

In the largest study of its kind researchers at the University of Cambridge have identified more than 380 genetic variants associated with the timing of puberty in men and women. The...

It’s been a perennial problem –biomedical research that largely leaves behind women and people with non-European ancestry. A newly published study by researchers at the University of California San Francisco...

Two new studies done by researchers in France and the United States connect the dots between the number of moles women have and their risk for developing breast cancer. Published...

In honor of the Chinese New Year, we’re taking one last look at the genetic milestones of 2013. From a Supreme Court ruling on patenting genes, to Angelina Jolie’s bold...

By Anne Pinckard The high rates of type 2 diabetes in some minority communities as well as the rates for prostate cancer among African American men are a good illustration...

Angelina Jolie’s revelation in the New York Times today that she had a double mastectomy after learning about her genetic risk for breast cancer focused attention on the difficult dilemma...

We know from scientific research that, in general, people don’t freak out about the results they get from personal genetic testing. When the results show an increased risk for serious...

Take a moment to look back at the ten most interesting and significant genetic findings of 2012 or at least the ones that drew our attention. In the last 12...